Torrent Pharmaceuticals stock (INE482A01020): Shares up 0.83% amid patent litigation developments

Torrent Pharmaceuticals shares rose 0.83% to 4,455.70 INR on NSE as of May 13, 2026, following a 2024 consent judgment in a US patent dispute with Novartis over heart drug generics.

Torrent Pharmaceuticals stock advanced 0.83% to 4,455.70 INR on the National Stock Exchange (NSE) on May 13, 2026, according to NSE India as of 05/13/2026. This modest gain comes amid ongoing interest in the company's US market exposure, highlighted by a sealed consent judgment in a patent case with Novartis resolved on July 8, 2024, restricting Torrent's generic sacubitril/valsartan sales in the US until the patent expires, per PatSnap as of 07/08/2024.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Torrent Pharmaceuticals Limited
• Sector/industry: Healthcare / Pharmaceuticals & Drugs
• Headquarters/country: India
• Core markets: India, US, Brazil
• Key revenue drivers: Generics, cardiovascular drugs
• Home exchange/listing venue: NSE (TORNTPHARM)
• Trading currency: INR

Torrent Pharmaceuticals: core business model

Torrent Pharmaceuticals Limited is an Indian multinational pharmaceutical company focused on developing, manufacturing, and marketing branded and generic medicines across therapeutic areas like cardiovascular, central nervous system, diabetology, and anti-infectives. The company operates in over 40 countries, with significant presence in emerging markets and the US generics space. Its business model emphasizes research-driven innovation alongside cost-effective generic production, as detailed on its official website.

Torrent's vertically integrated operations include R&D facilities in India, supported by four manufacturing plants compliant with US FDA standards. This setup enables the company to supply affordable drugs globally, with a portfolio exceeding 1,000 products. For US investors, Torrent's exposure to the world's largest pharma market via generics provides a play on pricing dynamics and regulatory approvals.

Main revenue and product drivers for Torrent Pharmaceuticals

Key revenue streams for Torrent Pharmaceuticals derive from branded generics in India (about 60% of sales) and exports to the US and Brazil. Cardiovascular drugs, including treatments for hypertension like telmisartan combinations, form a major pillar, with the company listed among top global players in this segment per Spherical Insights report. US generics contribute growing topline, despite patent hurdles.

Recent filings indicate steady demand for anti-diabetic and gastro-intestinal products. The company's pipeline includes complex generics targeting high-barrier US opportunities, balancing growth in domestic chronic therapy segments. This diversification appeals to US investors tracking pharma supply chains with India exposure.

Industry trends and competitive position

The global generics market faces pricing pressures but benefits from rising chronic disease prevalence, positioning Torrent Pharmaceuticals competitively against peers like Dr. Reddy's and Lupin. India's pharma sector supplies 20% of US generics, underscoring Torrent's relevance. Patent litigations, like the Novartis case, are common but often resolve with settlements enabling market entry post-exclusivity.

Why Torrent Pharmaceuticals matters for US investors

Torrent Pharmaceuticals offers US investors indirect exposure to India's booming pharma exports, which hit record highs in FY2024. With ANDA filings targeting the US$ 150 billion generics market, the stock tracks FDA approvals and Paragraph IV challenges. Its NSE listing provides liquidity, while ADR considerations could enhance accessibility.

Conclusion

Torrent Pharmaceuticals continues to navigate patent challenges in the US while leveraging its strong generics portfolio for growth in key markets. The recent share price uptick reflects market stability, with ongoing developments in cardiovascular generics warranting attention from global investors. Exposure to US FDA-regulated exports adds a layer of relevance for American portfolios tracking international pharma trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.